Medical Condition News

RSS

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Multiple Sclerosis Society of Canada to invite research operating grant proposals related to CCSVI and MS

The Multiple Sclerosis Society of Canada announced it will request research operating grants related to chronic cerebrospinal venous insufficiency (CCSVI) and MS.

25 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

Plasma albumin levels and cardiovascular disease risk factors influenced by common genetic components

Two indicators of liver function, glutamyl transferase (GGT) and albumin (ALB) have been implicated in the pathogenesis of atherosclerosis. It is known that the variation in the plasma level of these liver related proteins is genetically influenced.

25 Nov 2009

CVS/pharmacy and Warner Home Video team up to raise critical funds for cystic fibrosis

The Cystic Fibrosis Foundation announced today that CVS/pharmacy and Warner Home Video will partner with the Foundation this holiday season to raise critical funds for cystic fibrosis through the sale of classic family movies.

25 Nov 2009

New study reveals that dentists can help detect patients with cardiovascular disease

"Dentists are really proud of their profession and feel no need to encroach upon doctors' territory," says senior dental officer and professor Mats Jontell at the Sahlgrenska Academy. "However, we wanted to find out if we as a profession could identify patients at risk of cardiovascular disease."

25 Nov 2009

Study may pave way for potential drug targets in lung cancer treatment

Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

Exercise and education program reduces disability and improves physical function after back surgery

Patients who have undergone a single-level lumbar microdiskectomy for lumbar disk herniation experienced significant improvement in physical function following an intensive, progressive physical therapist guided exercise and education program, according to a research report published in the November issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association (APTA).

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

New Brunswick's colorectal cancer screening program lauded by CCAC

The Colorectal Cancer Association of Canada (CCAC) applauds the decision of the New Brunswick's Minister of Health Mary Schryer to implement a province wide colorectal cancer screening program and to provide funding for Avastin (bevacizumab) for patients with metastatic colorectal cancer.

25 Nov 2009

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.

25 Nov 2009

Study: GSTP gene protects against bowel cancer

CANCER RESEARCH UK scientists have shown that deleting a single gene can increase the average number of tumours in the bowel by 50-fold, according to research published in PNAS today.

25 Nov 2009

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th.

25 Nov 2009

Researchers develop new device to detect skin cancer

Researchers at Ben-Gurion University of the Negev are developing a new device that detects cancerous skin tumors, including melanomas that aren't visible to the naked eye.

25 Nov 2009

Study finds no significant difference in hospital angioplasty volume and death rates in patients with myocardial infarction

A study based on a contemporary registry of patients with myocardial infarction (heart attack) indicates that even though hospitals that perform a higher number of angioplasties are more likely to follow evidence-based guidelines and have shorter times to the angioplasty procedure, there appears to be no significant difference in outcomes such as length of hospital stay or risk of death, according to a study in the November 25 issue of JAMA.

25 Nov 2009

Older adults with chronic musculoskeletal pain face increase risk for falls

Older adults who reported chronic musculoskeletal pain in two or more locations, higher levels of severe pain, or pain that interfered with daily activities were more likely to experience a fall than adults who did not reports these types of pain, according to a study in the November 25 issue of JAMA.

25 Nov 2009

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

A recent study shows that 95 percent of radiation oncologists use advanced imaging techniques such as positron emission tomography (FDG-PET), magnetic resonance imaging (MRI), and 4-dimensional computed tomography (4DCT) for target delineation (to locate the tumor and other areas at risk for having cancer), according to an article in the December issue of the Journal of the American College of Radiology, (JACR, www.jacr.org).

25 Nov 2009

Eisai's NDA for Aricept tablets for treatment of Alzheimer's disease accepted for review

Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD).

25 Nov 2009

Medical Condition News

Human Genome Sciences submits BLA for ZALBIN

Multiple Sclerosis Society of Canada to invite research operating grant proposals related to CCSVI and MS

'Suicide gene E' reduces potent drug dosage in cancer patients

Plasma albumin levels and cardiovascular disease risk factors influenced by common genetic components

CVS/pharmacy and Warner Home Video team up to raise critical funds for cystic fibrosis

New study reveals that dentists can help detect patients with cardiovascular disease

Study may pave way for potential drug targets in lung cancer treatment

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

Exercise and education program reduces disability and improves physical function after back surgery

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

New Brunswick's colorectal cancer screening program lauded by CCAC

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Study: GSTP gene protects against bowel cancer

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

Researchers develop new device to detect skin cancer

Study finds no significant difference in hospital angioplasty volume and death rates in patients with myocardial infarction

Older adults with chronic musculoskeletal pain face increase risk for falls

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

Eisai's NDA for Aricept tablets for treatment of Alzheimer's disease accepted for review

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News